ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
2seventy bio Inc

2seventy bio Inc (TSVT)

3.95
-0.14
(-3.42%)
Closed June 16 4:00PM
3.95
-0.01
(-0.25%)
After Hours: 5:08PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.95
Bid
3.76
Ask
10.20
Volume
195,780
3.875 Day's Range 4.11
1.535 52 Week Range 11.29
Market Cap
Previous Close
4.09
Open
4.04
Last Trade
44
@
3.9883
Last Trade Time
Financial Volume
$ 771,980
VWAP
3.9431
Average Volume (3m)
791,734
Shares Outstanding
51,311,132
Dividend Yield
-
PE Ratio
-0.93
Earnings Per Share (EPS)
-4.24
Revenue
100.39M
Net Profit
-217.57M

About 2seventy bio Inc

2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
2seventy bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TSVT. The last closing price for 2seventy bio was $4.09. Over the last year, 2seventy bio shares have traded in a share price range of $ 1.535 to $ 11.29.

2seventy bio currently has 51,311,132 shares outstanding. The market capitalization of 2seventy bio is $203.19 million. 2seventy bio has a price to earnings ratio (PE ratio) of -0.93.

TSVT Latest News

2seventy bio to Participate in Upcoming Investor Conferences

2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.08-1.985111662534.034.293.723990444.01503051CS
4-1.04-20.84168336674.995.033.725473104.27199893CS
12-1.03-20.68273092374.985.993.447917344.77553905CS
260.617.91044776123.356.42.89511703584.59866007CS
52-7.04-64.058234758910.9911.291.53513895234.49454867CS
156-22.18-84.883275928126.1344.341.5358796668.53879158CS
260-22.18-84.883275928126.1344.341.5358796668.53879158CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
KAVLKaival Brands Innovations Group Inc
$ 5.96
(338.24%)
70.99M
LRHCLa Rosa Holdings Corporation
$ 1.165
(90.61%)
40.6M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
BRFHBarfresh Food Group Inc
$ 3.03
(38.36%)
247.31k
NNENano Nuclear Energy Inc
$ 9.37
(32.53%)
1.77M
NXLNexalin Technologies Inc
$ 0.89
(-35.52%)
3.93M
INABIN8bio Inc
$ 1.095
(-34.82%)
4.92M
QXOQXO Inc
$ 134.10
(-34.71%)
142.29k
GANXGain Therapeutics Inc
$ 1.24
(-34.39%)
3.09M
KYTXKyverna Therapeutics Inc
$ 9.52
(-34.07%)
4.31M
NVDANVIDIA Corporation
$ 131.88
(1.75%)
309.34M
SVMHSRIVARU Holding Ltd
$ 0.227586
(49.24%)
276.03M
KITTNauticus Robotics Inc
$ 0.1921
(19.69%)
165.83M
CRKNCrown Electrokinetics Corporation
$ 0.0582
(-21.35%)
136.77M
SQQQProShares UltraPro Short QQQ
$ 8.43
(-1.29%)
112.46M

TSVT Discussion

View Posts
Monksdream Monksdream 2 months ago
TSVT under $5
👍️0
Invest-in-America Invest-in-America 3 months ago
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 3 months ago
TSVT 10Q due March 5
👍️0
molee molee 4 months ago
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 6 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1 💩 1 🤡 1
johnhancoque johnhancoque 7 months ago
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 8 months ago
C'mon man . What the heck . $2.00 now ? Really ?
👍️0

Your Recent History

Delayed Upgrade Clock